Latest Fixed dose combination Stories
CORK, Ireland, December 29, 2014 /PRNewswire/ -- -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
December 1st is World AIDS day.
GENEVA, September 25, 2014 /PRNewswire/ -- MPP signs sub-licences with six generic manufacturers for the development of Phase III
New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV TORONTO, Sept. 17, 2014 /CNW/ - Janssen Inc.
Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information.
Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo.
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
- A volcanic mudflow.